Recent Drugs News & Articles

• New Application: Glumetza
  June 24, 2004 -- Biovail Corporation and Depomed, Inc. announced today that Biovail's NDA for Glumetza, a once-daily, extended-release formulation of metformin HCl...
  
  
• New Application: Oxypurinol
  June 24, 2004 -- Cardiome Pharma today announced that it has received an approvable letter from the FDA for oxypurinol for allopurinol-intolerant hyperuricemia (gout)...
  
  
• New Applicatiom: Palifermin
  June 24, 2004 -- Amgen Inc. today announced submission of a Biologics License Application for palifermin, a first-in-class investigational compound in development for oral mucositis (mouth sores)...
  
  
• New Approval: Codeprex
  June 22, 2004 -- The FDA has approved Codeprex (codeine polistirex / chlorpheniramine polistirex) Extended-Release Suspension CIII for cough relief...
  
  
• Spiriva Handihaler and 30-day capsule prescription now available to COPD patients...
  
  
• Health Canada proposes non-prescription status for ’morning after’ pill...
  
  
• U.S. approval for Octagam Immune Globulin Intravenous (Human) 5% in treatment of PID...
  
  
• FDA approves Taxotere in combination with prednisone for advanced prostate cancer...
  
  
• Survey: Severe conditions drive consumers to brand medications over generics...
  
  
• Vidaza approved as new orphan drug for bone marrow disease, following priority review...
  
  
• Research Analysis: More seniors hitting the Internet for health and pharmaceutical information...
  
  
• FDA approves Gemzar in combination with Taxol as first-line treatment for metastatic breast cancer...
  
  
• Approval for Avelox -- first I.V. antibiotic to treat resistant strains of most common bacterial pneumonia causes...
  
  
• FDA approves DepoDur (formerly DepoMorphine) for post-surgical pain relief...
  
  
• Approval for Apokyn in advanced Parkinson’s Disease treatment...
  
  
• Mucinex DM Extended Release Tablets approved for OTC distribution in time for winter...
  
  
• Barr’s Plan B OTC emergency contraceptive "not approvable"; FDA offers two options for further submissions...
  
  
• Recent FDA drug approvals
  
  
• New drug applications
  
  
• Pill Identification
  
  
• Professional Prescribing Information